MA26901A1 - Nouvelle composition pharmaceutique - Google Patents

Nouvelle composition pharmaceutique

Info

Publication number: MA26901A1
Authority: MA; Morocco
Prior art keywords: pharmaceutical composition; new pharmaceutical; pharmaceutically acceptable; erythropoiesis; prophylaxis
Prior art date: 2000-05-15

Application number

MA26907A

Other languages

English (en)

Inventor

Apollon Papadimitriou

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-15

Filing date

2002-11-13

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26901A1 publication Critical patent/MA26901A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Virology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA26907A 2000-05-15 2002-11-13 Nouvelle composition pharmaceutique MA26901A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00110355		2000-05-15

Publications (1)

Publication Number	Publication Date
MA26901A1 true MA26901A1 (fr)	2004-12-20

Family

ID=8168722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26907A MA26901A1 (fr)	2000-05-15	2002-11-13	Nouvelle composition pharmaceutique

Country Status (35)

Country	Link
US (2)	US7169754B2 (fr)
EP (2)	EP1311285B2 (fr)
JP (1)	JP3967594B2 (fr)
KR (3)	KR20070032815A (fr)
CN (1)	CN1309416C (fr)
AR (2)	AR035034A1 (fr)
AT (1)	ATE291436T2 (fr)
AU (1)	AU784091B2 (fr)
BR (1)	BRPI0110914B8 (fr)
CA (1)	CA2408685C (fr)
CZ (1)	CZ304855B6 (fr)
DE (1)	DE60109625T3 (fr)
DK (1)	DK1311285T4 (fr)
EC (2)	ECSP024352A (fr)
ES (1)	ES2237574T5 (fr)
HR (1)	HRP20020880B1 (fr)
HU (1)	HU230874B1 (fr)
IL (2)	IL152659A0 (fr)
JO (1)	JO3404B1 (fr)
MA (1)	MA26901A1 (fr)
ME (1)	MEP90708A (fr)
MX (1)	MXPA02011303A (fr)
MY (1)	MY128654A (fr)
NO (1)	NO330934B1 (fr)
NZ (1)	NZ522030A (fr)
PE (1)	PE20020050A1 (fr)
PL (1)	PL219131B1 (fr)
PT (1)	PT1311285E (fr)
RS (1)	RS51292B (fr)
RU (1)	RU2281116C2 (fr)
SI (1)	SI1311285T1 (fr)
TW (2)	TWI288644B (fr)
UY (1)	UY26704A1 (fr)
WO (1)	WO2001087329A1 (fr)
ZA (1)	ZA200208500B (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545553A (en) *	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7304150B1 (en) *	1998-10-23	2007-12-04	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
CZ299516B6 (cs)	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
ES2484966T3 (es) *	2000-04-12	2014-08-12	Novozymes Biopharma Dk A/S	Proteínas de fusión de albúmina
PT1311285E (pt) *	2000-05-15	2005-06-30	Hoffmann La Roche	Composicao farmaceutica liquida contendo um derivado de eritropoietina
ES2361824T3 (es)	2000-12-20	2011-06-22	F. Hoffmann-La Roche Ag	Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
EP1345628B1 (fr) *	2000-12-20	2011-04-13	F. Hoffmann-La Roche AG	Conjugues d'erythropoietine (epo) avec polyethylene glycol (peg)
FR2823220B1 (fr) *	2001-04-04	2003-12-12	Genodyssee	Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP1401477A4 (fr) *	2001-05-25	2005-02-02	Human Genome Sciences	Proteines hybrides beta-1 de chimiokine
US20030104996A1 (en) *	2001-08-30	2003-06-05	Tiansheng Li	L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
JP2003152145A (ja) *	2001-08-31	2003-05-23	Sumitomo Electric Ind Ltd	半導体放熱用基板とその製造方法及びパッケージ
US8008252B2 (en)	2001-10-10	2011-08-30	Novo Nordisk A/S	Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en)	2001-11-28	2007-01-02	Neose Technologies, Inc.	Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) *	2001-10-10	2010-09-14	Novo Nordisk A/S	Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) *	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
US7399613B2 (en) *	2001-10-10	2008-07-15	Neose Technologies, Inc.	Sialic acid nucleotide sugars
US7696163B2 (en)	2001-10-10	2010-04-13	Novo Nordisk A/S	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7473680B2 (en)	2001-11-28	2009-01-06	Neose Technologies, Inc.	Remodeling and glycoconjugation of peptides
AU2002364587A1 (en) *	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (fr)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
EP2277888A3 (fr) *	2001-12-21	2011-04-27	Human Genome Sciences, Inc.	Protéine chimérique d'albumine et érythropoïetine
MXPA04012496A (es) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
SI21258A (sl) *	2002-07-17	2004-02-29	LEK farmacevtska dru�ba d.d.	Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol
US7459435B2 (en) *	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
EP1545586A4 (fr) *	2002-09-09	2007-09-26	Warren Pharmaceuticals Inc	Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene
ZA200502320B (en) *	2002-09-20	2006-10-25	Pharmacia Corp	Process for decreasing aggregate levels of pegylated protein
US7459436B2 (en) *	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
CA2519092C (fr) *	2003-03-14	2014-08-05	Neose Technologies, Inc.	Polymeres hydrosolubles ramifies et conjugues de ceux-ci
EP1613261A4 (fr) *	2003-04-09	2011-01-26	Novo Nordisk As	Formation intracellulaire de conjugues de peptides
EP1615945B1 (fr)	2003-04-09	2011-09-28	BioGeneriX AG	Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US8791070B2 (en)	2003-04-09	2014-07-29	Novo Nordisk A/S	Glycopegylated factor IX
WO2007022512A2 (fr) *	2005-08-19	2007-02-22	Neose Technologies, Inc.	Facteur vii et facteur viia glycopegyle
ATE540055T1 (de) *	2003-05-09	2012-01-15	Biogenerix Ag	Zusammensetzungen und verfahren zur herstellung von glykosylierungsmutanten des menschlichen wachstumshormons
WO2004101600A2 (fr) *	2003-05-12	2004-11-25	Affymax, Inc.	Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
NZ543934A (en)	2003-05-12	2008-06-30	Affymax Inc	Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
PL1625156T3 (pl) *	2003-05-12	2013-03-29	Affymax Inc	Peptydy wiążące się do receptora erytropoetyny
UA88146C2 (ru)	2003-05-12	2009-09-25	Афимакс, Инк.	Новые пептиды, которые связываются с рецептором эритропоэтина
CA2528988C (fr) *	2003-06-10	2012-05-01	Lg Life Sciences Ltd.	Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique
WO2005012484A2 (fr)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Conjugues anticorps-toxines
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
US8633157B2 (en) *	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
EP1694347B1 (fr) *	2003-11-24	2013-11-20	BioGeneriX AG	Erythropoiétine glycopegylée
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
AU2004296855B2 (en) *	2003-12-03	2011-01-06	Ratiopharm Gmbh	Glycopegylated Granulocyte Colony Stimulating Factor
US7956032B2 (en)	2003-12-03	2011-06-07	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) *	2003-12-03	2008-12-25	Neose Technologies, Inc.	Glycopegylated Factor Ix
ES2460671T3 (es)	2003-12-19	2014-05-14	F. Hoffmann-La Roche Ag	Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
US8361961B2 (en) *	2004-01-08	2013-01-29	Biogenerix Ag	O-linked glycosylation of peptides
JP2007519422A (ja) *	2004-02-02	2007-07-19	アンブレツクス・インコーポレイテツド	修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
DE202004020676U1 (de) *	2004-03-10	2005-11-10	Bioceuticals Arzneimittel Ag	Erythropoietin-Flüssigformulierung
US20050282751A1 (en) *	2004-03-19	2005-12-22	Ajinomoto Co., Inc.	Therapeutic agent for renal anemia
EP1726303A4 (fr) *	2004-03-19	2011-03-02	Ajinomoto Kk	Agent therapeutique pour l'anemie renale
EP1737484A1 (fr) *	2004-03-26	2007-01-03	Janssen Pharmaceutica N.V.	Combinaison de dosages d'erythropoietine
AR049580A1 (es) *	2004-07-07	2006-08-16	Lundbeck & Co As H	Epo carbamilada y metodo para su produccion
EP1771066A2 (fr)	2004-07-13	2007-04-11	Neose Technologies, Inc.	Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
WO2006020372A2 (fr) *	2004-07-23	2006-02-23	Neose Technologies, Inc.	Modification enzymatique de glycopeptides
US7772182B2 (en) *	2004-08-05	2010-08-10	Alza Corporation	Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) *	2004-08-05	2006-02-09	Kui Liu	Stable particle formulations of erythropoietin receptor agonists
US8268967B2 (en) *	2004-09-10	2012-09-18	Novo Nordisk A/S	Glycopegylated interferon α
SI2586456T1 (sl)	2004-10-29	2016-05-31	Ratiopharm Gmbh	Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
JP2006137678A (ja) *	2004-11-10	2006-06-01	Shionogi & Co Ltd	インターロイキン−２組成物
WO2006062685A2 (fr) *	2004-11-11	2006-06-15	Affymax, Inc.	Nouveaux peptides se liant au recepteur de l'erythropoietine
AU2005310189A1 (en) *	2004-11-11	2006-06-08	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
US20100009902A1 (en) *	2005-01-06	2010-01-14	Neose Technologies, Inc.	Glycoconjugation Using Saccharyl Fragments
NZ556436A (en)	2005-01-10	2010-11-26	Biogenerix Ag	Glycopegylated granulocyte colony stimulating factor
CA2595676A1 (fr) *	2005-01-25	2006-08-03	Apollo Life Sciences Limited	Molecules et leurs molecules chimeriques
WO2006105426A2 (fr) *	2005-03-30	2006-10-05	Neose Technologies, Inc.	Procede de fabrication pour la production de peptides cultives dans des lignees cellulaires d'insectes
US9187546B2 (en)	2005-04-08	2015-11-17	Novo Nordisk A/S	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070037886A1 (en) *	2005-04-26	2007-02-15	Ajinomoto Co., Inc.	Bone marrow erythroid progenitor cell(s) differentiation inducer
EP1888098A2 (fr) *	2005-05-25	2008-02-20	Neose Technologies, Inc.	Formulations d'erythropoietine glycopegylees
US20080255026A1 (en) *	2005-05-25	2008-10-16	Glycopegylated Factor 1X	Glycopegylated Factor Ix
US20110003744A1 (en) *	2005-05-25	2011-01-06	Novo Nordisk A/S	Glycopegylated Erythropoietin Formulations
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
AU2006295340B2 (en)	2005-08-05	2010-11-11	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
US20070072795A1 (en) *	2005-09-28	2007-03-29	Anton Haselbeck	Treatment of neurodegenerative disorders
US20090048440A1 (en) *	2005-11-03	2009-02-19	Neose Technologies, Inc.	Nucleotide Sugar Purification Using Membranes
EP1973559B1 (fr)	2005-11-23	2013-01-09	Acceleron Pharma Inc.	Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
CN101015684B (zh) *	2006-02-10	2011-08-24	华北制药集团新药研究开发有限责任公司	一种重组人红细胞生成素溶液制剂
WO2007108505A1 (fr) *	2006-03-22	2007-09-27	Chugai Seiyaku Kabushiki Kaisha	Préparation de solution d'érythropoïétine
US20080242607A1 (en) *	2006-07-21	2008-10-02	Neose Technologies, Inc.	Glycosylation of peptides via o-linked glycosylation sequences
KR101304081B1 (ko) *	2006-08-04	2013-09-05	프로롱 파마슈티컬스, 엘엘씨	수식된 에리스로포이에틴
US20100075375A1 (en) *	2006-10-03	2010-03-25	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates
BRPI0717505B8 (pt) *	2006-10-04	2021-05-25	Novo Nordisk As	conjugado de peptídeo e formulação farmacêutica
US20080207487A1 (en) *	2006-11-02	2008-08-28	Neose Technologies, Inc.	Manufacturing process for the production of polypeptides expressed in insect cell-lines
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
TW202021980A (zh)	2007-02-02	2020-06-16	美商艾瑟勒朗法瑪公司	衍生自ActRIIB的變體與其用途
KR20100016160A (ko)	2007-04-03	2010-02-12	바이오제너릭스 에이지	글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
US20090053167A1 (en) *	2007-05-14	2009-02-26	Neose Technologies, Inc.	C-, S- and N-glycosylation of peptides
US20080286341A1 (en) *	2007-05-16	2008-11-20	Sven-Borje Andersson	Buffered coated nicotine containing products
JP2010531135A (ja) *	2007-06-04	2010-09-24	ノボノルディスクアクティーゼルスカブ	Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化
JP5876649B2 (ja)	2007-06-12	2016-03-02	ラツィオファルムゲーエムベーハーｒａｔｉｏｐｈａｒｍＧｍｂＨ	ヌクレオチド糖の改良製造法
CA2692165A1 (fr) *	2007-06-25	2008-12-31	Amgen Inc.	Compositions d'agents de liaison specifiques vis-a-vis du facteur de croissance des hepatocytes
US7968811B2 (en) *	2007-06-29	2011-06-28	Harley-Davidson Motor Company Group, Inc.	Integrated ignition and key switch
CL2008002053A1 (es) *	2007-07-17	2009-05-22	Hoffmann La Roche	Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) *	2007-07-17	2009-05-29	Hoffmann La Roche	Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
SI2197919T1 (sl)	2007-08-27	2014-09-30	Ratiopharm Gmbh	Tekoäśa formulacija g-csf konjugata
US8207112B2 (en) *	2007-08-29	2012-06-26	Biogenerix Ag	Liquid formulation of G-CSF conjugate
CN101456911A (zh) *	2007-12-12	2009-06-17	江苏豪森药业股份有限公司	促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
WO2009089396A2 (fr) *	2008-01-08	2009-07-16	Neose Technologies, Inc.	Glycoconjugaison de polypeptides employant des oligosaccharyltransférases
CN101965200B (zh)	2008-02-27	2013-06-19	诺沃-诺迪斯克有限公司	缀合的因子ⅷ分子
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ES2949049T3 (es)	2008-08-14	2023-09-25	Acceleron Pharma Inc	Trampas de GDF
JP5632376B2 (ja) *	2008-09-23	2014-11-26	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	エリスロポエチンの精製
CN102482339B (zh)	2009-06-08	2015-06-17	阿塞勒隆制药公司	用于增加产热脂肪细胞的方法
KR20210034684A (ko)	2009-06-12	2021-03-30	악셀레론 파마 인코포레이티드	절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
ES2535268T3 (es)	2009-06-24	2015-05-07	F. Hoffmann-La Roche Ag	Caracterización de equipo de cromatografía reutilizable
BRPI0902481B8 (pt)	2009-07-31	2021-05-25	Soc Beneficente De Senhoras Hospital Sirio Libanes	composição farmacêutica compreendendo hemopressina e seu uso.
KR102606494B1 (ko) *	2009-08-13	2023-11-24	악셀레론 파마 인코포레이티드	적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
US20120264688A1 (en) *	2009-09-23	2012-10-18	Walter Hinderer	Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
AU2010322011B2 (en)	2009-11-17	2016-03-31	Acceleron Pharma Inc.	ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP5621052B2 (ja)	2010-12-21	2014-11-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	クロマトグラフィー装置の特徴決定
AR094821A1 (es)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN102816227A (zh) *	2012-08-30	2012-12-12	深圳赛保尔生物药业有限公司	回收促红细胞生成素的方法
RU2678117C2 (ru)	2012-11-02	2019-01-23	Селджин Корпорейшн	Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CU20140003A7 (es)	2014-01-08	2015-08-27	Ct De Inmunología Molecular Biofarmacuba	Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
CA2943906A1 (fr)	2014-03-29	2015-10-08	Intas Pharmaceuticals Ltd.	Composition pharmaceutique liquide d'erythropoietine conjuguee
BR112016029226A2 (pt)	2014-06-13	2017-10-17	Acceleron Pharma Inc	métodos e composições para o tratamento de úlceras
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11608357B2 (en)	2018-08-28	2023-03-21	Arecor Limited	Stabilized antibody protein solutions
EP3372242A1 (fr)	2017-03-06	2018-09-12	Ares Trading S.A.	Composition pharmaceutique liquide
EP3372241A1 (fr)	2017-03-06	2018-09-12	Ares Trading S.A.	Composition pharmaceutique liquide
WO2018184692A1 (fr) *	2017-04-07	2018-10-11	Ares Trading S.A.	Composition pharmaceutique liquide
PL3731873T3 (pl) *	2017-12-29	2022-04-25	F. Hoffmann-La Roche Ag	Sposób dostarczania kompozycji pegylowanego białka
CN111558046A (zh) *	2020-05-27	2020-08-21	华润昂德生物药业有限公司	海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用
TWI740635B (zh) *	2020-09-09	2021-09-21	財團法人工業技術研究院	聚偏氟乙烯薄膜組成物及聚偏氟乙烯隔離膜

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US147431A (en) *		1874-02-10		Improvement in game boards
US115833A (en) *		1871-06-13		Improvement in grain-driers
JPS6197229A (ja) *	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
US4732889A (en) *	1985-02-06	1988-03-22	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
DE3734923C1 (de) *	1987-10-15	1989-01-26	Biotest Pharma Gmbh	Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE4014654A1 (de)	1990-05-08	1991-11-14	Behringwerke Ag	Galenische waessrige formulierungen von erythropoietin und ihre verwendung
EP0503050A4 (en) *	1990-09-28	1994-07-06	Ortho Pharma Corp	Hybrid growth factors
US5272135A (en) *	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
NZ244778A (en)	1991-10-21	1994-03-25	Ortho Pharma Corp	Peg imidates and protein derivatives thereof
DE4135542A1 (de)	1991-10-28	1993-04-29	Boehringer Mannheim Gmbh	Lagerfaehige proteinloesungen
US5460944A (en) *	1991-10-28	1995-10-24	Boehringer Mannheim Gmbh	Storable protein solution
US5716644A (en) *	1992-06-11	1998-02-10	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) *	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
US5354934A (en) †	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
WO1994028024A1 (fr)	1993-06-01	1994-12-08	Enzon, Inc.	Polymere modifie aux glucides presentant une activite erythropoïetique
ZA946122B (en) *	1993-08-17	1995-03-20	Amgen Inc	Erythropoietin analogs
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
TWI240627B (en) *	1996-04-26	2005-10-01	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
ATE341344T1 (de) *	1996-08-02	2006-10-15	Ortho Mcneil Pharm Inc	Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
US5919656A (en) *	1996-11-15	1999-07-06	Amgen Canada Inc.	Genes encoding telomerase protein 1
EP0885613A1 (fr) *	1997-06-21	1998-12-23	Roche Diagnostics GmbH	Application d'hémoglobine modifiée au traitement d'anémies et préparations mixtes à base d'hémoglobine modifiée et d'érythropoiétine
DE19734293A1 (de) *	1997-08-08	1999-02-11	Boehringer Mannheim Gmbh	Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
ATE355303T1 (de)	1998-10-23	2006-03-15	Amgen Inc	Methoden und zusammensetzungen zur prävention und behandlung der anämie
UY25790A1 (es)	1998-11-06	2000-08-21	Bio Sidus S A	Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
ATE401908T1 (de) *	1999-04-09	2008-08-15	Ortho Mcneil Pharm Inc	Pharmazeutische zusammensetzungen von erythropoietin
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
PE20010288A1 (es) *	1999-07-02	2001-03-07	Hoffmann La Roche	Derivados de eritropoyetina
CZ299516B6 (cs)	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
HRP20020159B1 (en)	1999-07-22	2007-08-31	Aventis Pharmaceuticals Inc.	Multi-dose erythropoietin formulations
US7253142B1 (en) †	1999-09-08	2007-08-07	Chugai Seiyaku Kabushiki Kaisha	Protein solution preparation and method of stabilizing the same
US7163671B2 (en) *	2000-02-29	2007-01-16	Chugai Seiyaku Kabushiki Kaisha	Long-term stabilized formulations
US6586398B1 (en) *	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
PT1311285E (pt) *	2000-05-15	2005-06-30	Hoffmann La Roche	Composicao farmaceutica liquida contendo um derivado de eritropoietina
WO2002011753A1 (fr) *	2000-08-04	2002-02-14	Chugai Seiyaku Kabushiki Kaisha	Preparations proteiniques a injecter
ES2361824T3 (es) *	2000-12-20	2011-06-22	F. Hoffmann-La Roche Ag	Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
US20030104996A1 (en) *	2001-08-30	2003-06-05	Tiansheng Li	L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US6818613B2 (en) *	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins

2001
- 2001-05-08 PT PT01943331T patent/PT1311285E/pt unknown
- 2001-05-08 EP EP01943331.7A patent/EP1311285B2/fr not_active Expired - Lifetime
- 2001-05-08 ES ES01943331.7T patent/ES2237574T5/es not_active Expired - Lifetime
- 2001-05-08 CZ CZ2002-4005A patent/CZ304855B6/cs not_active IP Right Cessation
- 2001-05-08 ME MEP-907/08A patent/MEP90708A/xx unknown
- 2001-05-08 DK DK01943331.7T patent/DK1311285T4/en active
- 2001-05-08 IL IL15265901A patent/IL152659A0/xx unknown
- 2001-05-08 HU HU0302114A patent/HU230874B1/hu unknown
- 2001-05-08 DE DE60109625.8T patent/DE60109625T3/de not_active Expired - Lifetime
- 2001-05-08 HR HR20020880A patent/HRP20020880B1/xx not_active IP Right Cessation
- 2001-05-08 AT AT01943331T patent/ATE291436T2/de active
- 2001-05-08 RU RU2002133236/15A patent/RU2281116C2/ru active
- 2001-05-08 KR KR1020077003371A patent/KR20070032815A/ko not_active Ceased
- 2001-05-08 EP EP05000984A patent/EP1525889A1/fr not_active Withdrawn
- 2001-05-08 SI SI200130331T patent/SI1311285T1/xx unknown
- 2001-05-08 NZ NZ522030A patent/NZ522030A/en not_active IP Right Cessation
- 2001-05-08 BR BRPI0110914A patent/BRPI0110914B8/pt not_active IP Right Cessation
- 2001-05-08 PL PL361341A patent/PL219131B1/pl unknown
- 2001-05-08 CA CA2408685A patent/CA2408685C/fr not_active Expired - Lifetime
- 2001-05-08 RS YUP-835/02A patent/RS51292B/sr unknown
- 2001-05-08 AU AU65934/01A patent/AU784091B2/en not_active Expired
- 2001-05-08 MX MXPA02011303A patent/MXPA02011303A/es active IP Right Grant
- 2001-05-08 JP JP2001583796A patent/JP3967594B2/ja not_active Expired - Lifetime
- 2001-05-08 KR KR1020027015429A patent/KR100758044B1/ko not_active Expired - Lifetime
- 2001-05-08 WO PCT/EP2001/005187 patent/WO2001087329A1/fr not_active Ceased
- 2001-05-08 KR KR1020057023568A patent/KR20050121762A/ko not_active Ceased
- 2001-05-08 CN CNB018095607A patent/CN1309416C/zh not_active Expired - Lifetime
- 2001-05-09 JO JOP/2001/0065A patent/JO3404B1/ar active
- 2001-05-11 US US09/853,731 patent/US7169754B2/en not_active Expired - Lifetime
- 2001-05-11 MY MYPI20012197A patent/MY128654A/en unknown
- 2001-05-11 PE PE2001000421A patent/PE20020050A1/es active IP Right Grant
- 2001-05-11 AR ARP010102248A patent/AR035034A1/es not_active Application Discontinuation
- 2001-05-14 UY UY26704A patent/UY26704A1/es not_active IP Right Cessation
- 2001-05-14 TW TW094134688A patent/TWI288644B/zh not_active IP Right Cessation
- 2001-05-14 TW TW090111453A patent/TWI288643B/zh not_active IP Right Cessation
2002
- 2002-10-21 ZA ZA200208500A patent/ZA200208500B/en unknown
- 2002-11-05 IL IL152659A patent/IL152659A/en active IP Right Grant
- 2002-11-13 MA MA26907A patent/MA26901A1/fr unknown
- 2002-11-14 NO NO20025450A patent/NO330934B1/no not_active IP Right Cessation
- 2002-11-20 EC EC2002004352A patent/ECSP024352A/es unknown
2004
- 2004-02-17 US US10/780,297 patent/US7202208B2/en not_active Expired - Lifetime
2010
- 2010-12-21 EC EC2010004352A patent/ECSP10004352A/es unknown
2013
- 2013-10-04 AR ARP130103618A patent/AR092919A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2408685A1 (fr)	2001-11-22
HRP20020880A2 (en)	2004-12-31
BR0110914A (pt)	2003-02-11
ATE291436T2 (de)	2005-04-15
TWI288644B (en)	2007-10-21
MY128654A (en)	2007-02-28
BRPI0110914B1 (pt)	2016-03-01
JO3404B1 (ar)	2019-10-20
CA2408685C (fr)	2011-02-01
RS51292B (sr)	2010-12-31
CN1309416C (zh)	2007-04-11
HUP0302114A3 (en)	2012-12-28
EP1311285B1 (fr)	2005-03-23
ES2237574T3 (es)	2005-08-01
ECSP024352A (es)	2003-03-31
MXPA02011303A (es)	2003-04-25
BRPI0110914B8 (pt)	2021-05-25
TWI288643B (en)	2007-10-21
PL219131B1 (pl)	2015-03-31
EP1311285A2 (fr)	2003-05-21
UY26704A1 (es)	2001-12-28
HK1056683A1 (en)	2004-02-27
HU230874B1 (hu)	2018-11-29
AU6593401A (en)	2001-11-26
EP1525889A1 (fr)	2005-04-27
ZA200208500B (en)	2004-01-28
NO330934B1 (no)	2011-08-22
ECSP10004352A (es)	2011-01-31
DE60109625D1 (de)	2005-04-28
PE20020050A1 (es)	2002-02-01
HRP20020880B1 (en)	2006-04-30
US20040147431A1 (en)	2004-07-29
AR092919A2 (es)	2015-05-06
IL152659A (en)	2010-12-30
HUP0302114A2 (hu)	2003-10-28
US20020037841A1 (en)	2002-03-28
KR20070032815A (ko)	2007-03-22
DK1311285T4 (en)	2017-07-24
NZ522030A (en)	2004-11-26
KR100758044B1 (ko)	2007-09-11
US7202208B2 (en)	2007-04-10
ME00673B (fr)	2011-12-20
US7169754B2 (en)	2007-01-30
AU784091B2 (en)	2006-02-02
PT1311285E (pt)	2005-06-30
RU2281116C2 (ru)	2006-08-10
NO20025450D0 (no)	2002-11-14
KR20050121762A (ko)	2005-12-27
DE60109625T2 (de)	2006-03-30
WO2001087329A1 (fr)	2001-11-22
DE60109625T3 (de)	2017-08-03
YU83502A (sh)	2005-11-28
IL152659A0 (en)	2003-06-24
SI1311285T1 (fr)	2005-08-31
KR20030001509A (ko)	2003-01-06
NO20025450L (no)	2002-11-14
ES2237574T5 (es)	2017-08-09
PL361341A1 (pl)	2004-10-04
CZ304855B6 (cs)	2014-12-10
JP3967594B2 (ja)	2007-08-29
WO2001087329A8 (fr)	2002-03-07
CN1429116A (zh)	2003-07-09
AR035034A1 (es)	2004-04-14
DK1311285T3 (da)	2005-06-27
EP1311285B2 (fr)	2017-04-12
MEP90708A (hr)	2011-12-20
JP2003533487A (ja)	2003-11-11
CZ20024005A3 (cs)	2004-01-14

Publication	Publication Date	Title
MA26901A1 (fr)	2004-12-20	Nouvelle composition pharmaceutique
EA200100524A1 (ru)	2002-02-28	Амиды антраниловой кислоты и их применение в качестве лекарственных средств
NO963499L (no)	1996-10-14	Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
EA200300248A1 (ru)	2003-08-28	Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
MXPA04000920A (es)	2004-04-02	Derivados de aminoisoxazol activos como inhibidores de la cinasa.
EE03969B1 (et)	2003-02-17	(Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
MY106315A (en)	1995-04-29	Pharmaceutical agents
EA200400476A1 (ru)	2004-08-26	Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
WO2001098290A3 (fr)	2002-05-16	Derives de thiophene actifs en tant qu'inhibiteurs de kinase, leur procede de preparation, et compositions pharmaceutiques les contenant
BR0109650A (pt)	2003-04-22	3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
BR0015416A (pt)	2002-07-16	Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BR9909958A (pt)	2000-12-26	Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
IT1265101B1 (it)	1996-10-30	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
BR9914128A (pt)	2002-09-24	Composições antibióticas para tratamento do olho, ouvido e nariz
ATE287886T1 (de)	2005-02-15	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
BR9611642A (pt)	1999-06-01	Compostos composição farmacéutica e processo para a preparação de compostos
BR9609847A (pt)	1999-03-09	Derivados de N-(4-Benzila-substituída)-2-aminolactam
ATE225171T1 (de)	2002-10-15	Aminosäurederivate zur behandlung von schlaganfall
DE60322064D1 (de)	2008-08-21	4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
MXPA03011502A (es)	2004-03-26	Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
SE0001916D0 (sv)	2000-05-23	Novel formulation
TR200003451T2 (tr)	2001-04-20	Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
ATE241640T1 (de)	2003-06-15	Fusidinsäure-derivate
DE50212538D1 (de)	2008-09-04	Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
IT1307866B1 (it)	2001-11-19	Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento